Determinación del comportamiento del riesgo cardiovascular en paciente postrasplante hepatico en Fundacion Cardioinfantil
| Contribuinte(s) |
Rodríguez, Nelcy Barrera Garavito, Edgar Camilo |
|---|---|
| Data(s) |
01/08/2016
31/12/1969
|
| Resumo |
El trasplante hepático es una opción terapéutica para enfermedad hepática avanzada cada vez más frecuente en Colombia. La sobrevida del 80% a 5 años conlleva a un aumento del riesgo cardiovascular y de eventos cardiovasculares, por esta razón esta investigación determina el comportamiento del riesgo cardiovascular en los pacientes con trasplante hepático de la Fundación Cardioinfantil, realizado en 3 años de seguimiento . Lo encontrado en esta investigación es que existe un aumento del riesgo cardiovascular a tres años en pacientes post trasplante hepático, estadísticamente significativo, principalmente secundario a hipertensión, diabetes e hipertrigliceridemia. El aumento es mayor a lo descrito en la población general, y similar a otros pacientes trasplantados, en un periodo de 5 años Liver transplantation is an therapeutic option increasingly common in Colombia for advanced liver disease. The survival of 80% at 5 years leads to an increased cardiovascular risk and cardiovascular events, for this reason this research determines the behavior of cardiovascular risk in patients with liver transplant Cardioinfantil Foundation. Finding there is an increased cardiovascular risk in patients three years after transplantation statistically significant, mainly secondary to hypertension, diabetes and hypertriglyceridemia. The increase is larger as described in the general population, and similar to other transplant patients over a period of 5 years. |
| Formato |
application/pdf |
| Identificador | |
| Idioma(s) |
spa |
| Publicador |
Facultad de Medicina |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
instname:Universidad del Rosario reponame:Repositorio Institucional EdocUR Mejía G, Varón A, Santos LF, Hernández G, Castro D, Rubio J, Rivera J, Benavides C, Beltrán O, Ponce de León E, Ceballos J, Garzón M, Suarez M, Ordoñez F, Ibarra MT, Martínez D, Blanco AI, Ríos LD BR. Trasplante hepatico experiencia de la fundacion cardioinfantil. 2012. Rossetto a., Baccarani U, Adani GL. Cardiovascular Risk Factors and Liver Transplantation. Minireview. J Transplant Technol Res [Internet]. 2012;02(01):1–6. Available from: http://www.omicsonline.org/2161-0991/2161-0991-2-109.digital/2161-0991-2-109.html Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl [Internet]. 2013;19(1):3–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23281277 Rubín A, Sánchez-Montes C, Aguilera V, Juan FS, Ferrer I, Moya A, et al. Long-term outcome of “long-term liver transplant survivors.” Transpl Int. 2013;26(7):740–50 Mazen Albeldawi, 1 Ashish Aggarwal, 2 Surabhi Madhwal, 6 Jacek Cywinski, 3 Rocio Lopez 4, Bijan Eghtesad 5 and Nizar N. Zein. Cumulative Risk of Cardiovascular Events After Orthotopic Liver Transplantation. Liver Transplant. 2012 Desai S, Hong JC, Saab S. Cardiovascular risk factors following orthotopic liver transplantation: Predisposing factors, incidence and management. Liver Int. 2010;30(7):948–57Desai S, Hong JC, Saab S. Cardiovascular risk factors following orthotopic liver transplantation: Predisposing factors, incidence and management. Liver Int. 2010;30(7):948–57 Mansell H, Worobetz LJ, Sylwestrowicz T, Shoker AS. A retrospective study of the Framingham cardiovascular risk scores in a liver transplant population. Transplant Proc [Internet]. 2013;45(1):308–14. Available from: http://dx.doi.org/10.1016/j.transproceed.2012.04.039 Neal DAJ, Tom BDM, Luan J, Wareham NJ, Gimson AES, Delriviere LD, et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation [Internet]. 2004;77(1):93–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14724441 Muñoz OM, Rodríguez NI, Ruiz Á, Rondón M. Validación de los modelos de predicción de Framingham y PROCAM como estimadores del riesgo cardiovascular en una población colombiana. Rev Colomb Cardiol [Internet]. 2014;21(4):202–12. Available from: http://www.sciencedirect.com/science/article/pii/S0120563314000126 Schargrodsky H, Hernandez R, Champagne BM, Silva H, Vinueza R, Silva Ayaguer LC, et al. CARMELA: Assessment of Cardiovascular Risk in Seven Latin American Cities. Am J Med. 2008;121(1):58–65 Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation [Internet]. 2002;73(6):901–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11923689 Surabhi Madhwal, Ashish Atreja, Mazen Albeldawdi, Rocio Lopez AP, Costa and MA. Is Liver Transplantation a Risk Factor for Cardiovascular Disease? A Meta-Analysis of Observational Studies. Liver Transplant. 2012;18:1140-11 Organization WH. Global status report on noncommunicable diseases 2010. In 2011 Salud O nacional de. Enfermedad cardiovascular: principal causa de muerte en Colombia [Internet]. Available from: http://www.ins.gov.co/Paginas/inicio.aspx Adolfo Vera-Delgado et al. GUÍAS DE PREVENCIÓN PRIMARIA EN RIESGO CARDIOVASCULAR “TÓPICOS SELECTOS.” Revista colombiana de cardiología; 2009. 268 p Gonz AI, Carlos J, Rebollar O. Actualización: ¿que tabla es más adecuada para el cálculo del riesgo coronario en atencion primaria? www.jano.es. 2009;19–24. José María Lobos Bejaranoa CBC. Factores de riesgo cardiovascular y atención primaria: evaluación e intervención. Atención Primaria ELSEVIER. 2011;43(12):668–77. Torres Y, Jaramillo NI. Aspectos epidemiológicos de la enfermedad cardiovascular: factores de riesgo a la luz de Framingham. Rev CES Med. 2004;18(2):45–68. Lee KK HM. Reynolds Risk Score for men predicted cardiovascular events more accurately than traditional risk factors only. Ann Intern Med [Internet]. 2009;17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19306496 Pencina MJ, Sr RBDA, Larson MG, Massaro JM, Vasan RS. Predicting the Thirty-Year Risk of Cardiovascular Disease: The Framingham Heart Study. Circulation. 2009;119(24):3078–84. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A BP. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. Br Med J. 2008 Rana JS, Tabada GH, Solomon MD, Lo JC, Jaffe MG, Sung SH, et al. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population. J Am Coll Cardiol [Internet]. 2016;67(18):2118–30. Available from: http://www.sciencedirect.com/science/article/pii/S0735109716010251 Richard J. Stevens, PHD, Ruth L. Coleman, BSC, Amanda I. Adler, FRCP, Irene M. Stratton, MSC, David R. Matthews, FRCP and Rury R. Holman F. Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabete. Diabetes Care [Internet]. 2004;27(1): 201. Available from: http://dx.doi.org/10.2337/diacare.27.1.201 Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129(25 SUPPL. 1) Salud O nacional de. Mortalidad 1998-2011 y situación de salud en los municipios de frontera terrestre en Colombia. Imprenta Nacional de Colombia, Bogotá, D.C.,Segundo Informe ONS. Bogota, DC; 2013. Bianchi G, Marchesini G, Marzocchi R, Pinna AD ZM. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transplant. 2008;14(11):164 Fernandez-Miranda C, Sanz M, dela Calle A, Loinaz C, Gomez R, Jimenez C et al. Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation. Transpl Int. 2002;5:556-562 Neal DA1, Gimson AE, Gibbs P AG. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transplant. 2001;7(6):533-9 Rabkin JM, Corless CL, Rosen HR OA. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg. 2002;183(5):595. M. José Medranoa, Elena Cerratoa, Raquel Boixa MD-R. Factores de riesgo cardiovascular en la población española: metaanálisis de estudios transversales. Med Clin (Barc). 2005;124. Núm. . Stegall MD1, Everson G, Schroter G, Bilir B, Karrer F KI. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation. 1995;5;60(9):10. Guckelberger O1, Bechstein WO, Neuhaus R, Luesebrink R, Lemmens HP, Kratschmer B, Jonas S NP. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant. 1997;11(1):60-5. E Varoa, E Padina, E Oteroa, S Toméa, J.F Castroagudina, M Delgadoa, R Condea, F.R Segadea, C Mellaa AG-Q. Cardiovascular risk factors in liver allograft recipients: Relationship with immunosuppressive therapy. Transplant Proc. 2002;34(5) Kniepeiss D1, Iberer F, Schaffellner S, Jakoby E, Duller D TK. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transplant. 2004;18(6):642. Cronin DC 2nd1, Faust TW, Brady L, Conjeevaram H, Jain S, Gupta P MJ. Modern immunosuppression. Clin Liver Dis. 2000;4(3):619-5 Watt KD, Fan C, Therneau T, Heimbach JK, Seaberg EC, Charlton MR. Serum Adipokine & Inflammatory Markers Before and After Liver Transplantation in Recipients with Major Cardiovascular Events. Liver Transpl. 2014;20(7):791–7. Berenguer M1, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, Risalde B, Rubin A, Cañada R, Palau A RJ. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transplant. 2009;15(7):738. Mazuelos F , Abril J , Zaragoza C , Rubio E , Moreno JM , Turrión VS C-M V. Cardiovascular morbidity and obesity in adult liver transplant recipients. Transplant Proc. 2003;35(5):1909 Bastard JP1, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J FB. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12 Lau DC1, Dhillon B, Yan H, Szmitko PE VS. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Hear Circ Physiol. 2005;288(5):H20. Anty R1 LM. Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol. 2011;35 Suppl 1 Olarte Parra, Camila; Otero Arrázola LM. Supervivencia en pacientes con trasplante hepático realizado en la Fundación Cardioinfantil entre 2005 y 2013. Universidad del Roario; 2013 Munagala MR, Phancao A. Managing Cardiovascular Risk in the Post Solid Organ Transplant Recipient. Med Clin North Am [Internet]. 2016;100(3):519–33. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0025712516000055 Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries in a case-control study based on the INTERHEART study. Lancet. 2004;364:937–52. |
| Palavras-Chave | #Medicina interna #616 #Medicina inerna #Enfermedades cardiovasculares #Trasplante de hígado #Enfermedad hepática #Risk #Cardiovascular Diseases #Liver Transplantation |
| Tipo |
info:eu-repo/semantics/bachelorThesis info:eu-repo/semantics/acceptedVersion |
